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retinitis, duodenal and/or colonic involvement, or dissemi-Cytomegalovirus (CMV) is a significant cause of morbidity
nated disease.2-4 CMV infection after OLT has been linked toin immunosuppressed patients. It is characterized in the liver
decreased patient survival, particularly in studies publishedby parenchymal microabscesses, usually containing CMV-in-
before the availability of CMV-specific antivirals.2,3,5-10 Strattafected cells. However, not all hepatic microabscesses are due
et al.6 found that CMV infection in OLT recipients is associ-to CMV infection. In 1992, we described ‘‘mini’’ microabscess
ated with increases in the duration of the peritransplant hos-(MMA) syndrome, a distinct clinical syndrome that occurs
pital stay (38-80 days) and the average costs of these admis-in transplanted livers. This report analyzes the clinical and
sions (US$100,000-250,000).laboratory features of 57 cases of MMA syndrome occurring
CMV infection usually occurs in the first 3 months afterin 52 patients and compares these with 19 biopsy-proven
OLT.2,4,6 CMV infection of the liver tends to be focal andcases of CMV infection. The diagnosis of MMA syndrome can
may affect hepatocytes, bile duct epithelium, endothelium,only be made histologically. The microabscesses are smaller
or any combination of these sites. Infected cells often containand more numerous than in CMV infection, and there are no
a single large eosinophilic nuclear inclusion surrounded byviral inclusions present. CMV DNA could not be detected in
a halo, and/or numerous amphophilic granular cytoplasmicliver biopsy specimens with MMAs by using ‘‘nested’’ poly-
inclusions.11 In the hepatic lobule, the infected cells are oftenmerase chain reaction (PCR), indicating that MMA syndrome
surrounded by a collection of neutrophils, forming a mi-is not caused by CMV infection. The pattern of liver enzyme
croabscess. Occasionally a microabscess may lack morpho-and bilirubin elevation is predominantly hepatocellular, with
logically infected cells.12 In this setting, the presence of mi-transaminase levels elevated, on average, six to eight times
croabscesses, even in the absence of typical CMV infectedthe upper limit of normal. The clinical features of MMA syn- cells, could be interpreted as evidence of CMV infection.
drome are that it predominantly affects female (40 of 52 pa- Currently, CMV infection in OLT recipients can usually
tients) orthotopic liver transplant (OLT) recipients of all ages be successfully treated with ganciclovir.3,6,13 Because of the
(range, 11 months to 66.9 years). MMA syndrome is unrelated significant costs of untreated CMV infection in OLT recipi-
to the indication for initial OLT and tends to occur later after ents, several groups have stressed the need for a high index
transplantation than CMV infection (median, 91 days post- of suspicion for CMV infection post-OLT and have supported
OLT vs. 32 days for CMV hepatitis). Although the etiology an aggressive approach to the diagnosis and treatment of
of MMA syndrome is not clear, it does not appear to adversely CMV infection.2,8,13,14 However, ganciclovir therapy is expen-
affect graft or patient survival. (HEPATOLOGY 1997;26:192- sive in terms of both nursing time and the cost of the drug.
197.) Intravenous therapy with ganciclovir also carries the risk
of systemic bacterial infection and other complications of
Cytomegalovirus (CMV) infection is a major cause of mor- intravenous access in this already-compromised population.
bidity in immunosuppressed patients, particularly transplant In 1992, we described a novel lesion, ‘‘mini’’-microab-
recipients.1 In orthotopic liver transplant (OLT) recipients, scesses (MMAs), seen in 14 liver biopsy specimens from
CMV infection can result in hepatitis, pneumonitis, chorio- OLT recipients.15 When MMAs were first seen, they were
considered evidence of CMV infection and treated accord-
ingly. However, as our experience grew, MMAs appeared
Abbreviations: CMV, cytomegalovirus; OLT, orthotopic liver transplant; MMA, mini- histologically and clinically distinct from CMV-associated
microabscess; AST, aspartate transaminase; ALT, alanine transaminase; PCR, polymer-
microabscesses. MMAs were smaller and more numerousase chain reaction; CI, confidence interval.
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TABLE 1. Indication for Initial Liver TransplantationCenter, with 64 of these patients receiving a second OLT, 6 a third,
and 3 a fourth transplant. During that time, 2,210 OLT liver biopsies
Indication for OLT n*
were performed at the University of Michigan. All biopsies with a
diagnosis of microabscesses were reviewed by one of the authors Cryptogenic cirrhosis† 16
(J.K.G.). Nineteen biopsies had clear evidence of CMV infection Cirrhosis due to ethanol 7
with CMV inclusion bodies and were used to define the group with Fulminant hepatic failure‡ 5
CMV infection. Fifty-seven biopsies revealed multiple microab- Primary biliary cirrhosis 5
scesses but no evidence of CMV infection histologically. These 57 Primary sclerosing cholangitis 5
patients made up the MMA group and were used to define the Biliary atresia 4
histological and clinical features of MMA syndrome. Hepatitis C cirrhosis 4
The histological features studied were the number of neutrophils Autoimmune hepatitis 2
in each microabscess and the number of microabscesses per square Chronic hepatitis B cirrhosis 1
millimeter of biopsy material for the MMA and CMV biopsies. Clini- Alagille’s syndrome 1
cal features reviewed included indication for initial OLT, donor and Wilson’s disease 1
recipient sex, recipient age, delay from OLT to diagnosis of CMV Hepatoblastoma 1
infection or MMA syndrome, donor and recipient CMV status, and
* Fifty-two patients, with 57 episodes of minimicroabscess syndrome.the effect of MMA syndrome on 1- and 5-year graft and patient
† Includes 4 patients who received transplants prior to availability ofsurvival. The effect of CMV infection or MMA syndrome on peak
hepatitis C testing.bilirubin, aspartate transaminase (AST), alanine transaminase
‡ Includes 4 patients with non-A, non-B fulminant hepatic failure and 1(ALT), and alkaline phosphatase levels in the 3 days on either side
pregnant woman with HELLP syndrome.of the date of liver biopsy were reviewed.
Fourteen needle liver biopsy specimens with MMA syndrome, 19
with CMV inclusion bodies present, and 28 with neither CMV infec-
tion nor MMA were studied with the PCR for evidence of CMV DNA.
ln(time). Confidence intervals (95%) for estimates of survival ad-
PCR was performed on DNA extracted from unstained 5-mm tissue
justed for age, sex, and MMA status were estimated using Green-
sections of formalin-fixed, paraffin-embedded liver biopsy specimens
wood’s formula.17 The study protocol conformed to the ethical
using a technique previously described.16 In brief, DNA was extracted
guidelines of the 1975 Declaration of Helsinki.
by direct boiling of unstained tissue sections that had been deparaffin-
ized in xylene and 100% ethanol. Positive and negative controls con- RESULTS
sisted of a paraffin section of cytomegalovirus-infected lung and an
Fifty-seven separate episodes of minimicroabscess syn-empty ‘‘mock extraction’’ tube processed in parallel with patient sam-
drome were documented. These 57 biopsy specimens wereples. ‘‘Multiplex’’ amplification was performed in a single reaction for
portions of two CMV genes: the major intermediate early gene (CMV- taken from 52 patients, with 3 patients having two episodes
MIE), and the late antigen gene (CMV-LA), as well as for human b- and 1 patient three episodes of MMA. In those patients with
hemoglobin for verification of DNA extraction. The following synthetic more than one episode of MMA syndrome, there was at least
oligonucleotide primers were used: 5*-CCACCCGTGGTGCCA- one biopsy that showed no MMA or greater than 6 months
GCTCC-3* and 5*-CCCGCTCCTCCTGAGCACCC-3* (CMV-MIE), with normalization of transaminase levels during the interval
5*-AACCTGGTGCCCATGGTGGCTA-3* and 5*-TTTGGGTTGCGC- separating the episodes of MMA syndrome. Seven of the pa-
AGCGGGCTG-3* (CMV-LA gene), and 5*-CAGACACCATGGTGC-
tients with MMAs had undergone a second OLT, with MMAACCTGAC-3* and 5*-CCAATAGGCAGAGAGAGTCAGTG-3* (hu-
syndrome occurring after the second OLT in 4 of these 7man b-hemoglobin), resulting in PCR products of 162, 132, and 210
patients.base pairs, respectively. PCR was performed for 35 cycles of 947C for
There was a wide variety of primary indications for the1 minute, 647C for 2 minutes, and 727C for 2 minutes. Ten percent
initial OLTs in these patients (Table 1), including fulminantof the initial PCR reaction was subsequently used as a template for
an additional PCR of 35 cycles using the following internally ‘‘nested’’ hepatic failure, cirrhosis due to ethanol abuse and/or hepati-
oligonucleotide primers: 5*-TCTGATTCTCTGGTGTCACC-3* and 5*- tis C infection, biliary cirrhosis, both primary and secondary,
TCCTCCTCTTCCTCATCACT-3* (CMV-MIE gene), 5*-CGGTTC- and cryptogenic cirrhosis. Patients with MMAs showed a
AGGGTCAGAATCTG-3* and 5*-CCATACGCCTTCCAATTCGG-3* wide age range, with a median age at the time of first OLT
(CMV-LA gene), and 5*-TCCTGAGGAGAAGTCTGCC-3* and 5*-CCT- of 40.6 years (range, 11 months to 66.4 years). There was a
ATCAGAAACCCAAGAGTC-3* (human b-hemoglobin), resulting striking female predominance in patients with MMAs, with
in PCR products of 120, 89, and 165 base pairs, respectively. Condi-
40 of the patients being female and 12 male (P õ .0001).tions for the second-round PCR were the same as for the first except
Sex of the liver donor was not significantly associated withthat an annealing temperature of 547C rather than 647C was used.
MMA syndrome (Table 2). Thirty-three of the MMA patientsThe resulting PCR product was resolved by electrophoresis through
were CMV immunoglobulin G antibody–positive beforean agarose gel and directly visualized by UV illumination.
OLT, whereas 27 of their donors were positive. Nine patientsThe effects of OLT donor and recipient gender were analyzed by
x2 analysis. The time from OLT to diagnosis and the peak bilirubin with MMA syndrome had negative pre-OLT CMV serology
and liver enzyme levels were compared between MMA patients and for both recipient and donor, whereas data were incomplete
those with biopsy-proven CMV infection assuming nonparametric in a further 2. For patients with CMV, in 16 cases either the
distribution using the Mann-Whitney U test. Statistical analysis of donor (12 cases) and/or the recipient were CMV IgG positive,
survival was performed with age categorized into quintiles of the whereas data were incomplete for the remaining 3.
frequency distributions (up to 28 years, 29-40, 41-48, 49-56, and There was a significant difference in the time from OLT
57 or more years of age). Cox proportional hazards survival models
to diagnosis of either CMV infection or MMA syndrome.were used to estimate 1- and 5-year patient and graft survival rates.
Although there was some overlap, CMV occurred at a medianTime to diagnosis of MMA was incorporated into these models as
of 32 days post-OLT (range, 5-112 days), whereas MMAa time-dependent covariate, and it was assumed that MMA was not
syndrome occurred significantly later, at a median of 91 dayspresent until the diagnostic biopsy was performed. The propor-
post-OLT (range, 4-2,816 days, P Å .006). A typical clinicaltional-hazards assumption was tested by extending the final models
to include interaction terms of gender with ln(time) and age with presentation of patients with MMA syndrome was an inciden-
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TABLE 2. Relationship Between Sex of OLT Donor and Recipient
and Subsequent Diagnosis of MMA Syndrome
Male Recipient Female Recipient
Male Female Male Female
Donor Donor Donor Donor Total
MMA present 11 1 28 12 52
No MMA 161 69 138 89 457
Total 172 70 166 101 509*
NOTE. P ú.50 using the x2 test for homogeneity of odds ratio (Woolf
method).
* Donor sex was not available for two OLTs.
tal finding of marked elevation of transaminase levels de-
tected through routine blood work before an outpatient OLT
clinic visit. For several patients, liver enzyme levels had been
measured daily for 1 or more days before liver biopsy. The
increase in transaminase levels occurred suddenly, over only
1 or 2 days. These biochemical abnormalities would result
in sufficient clinical concern for a liver biopsy to be per-
formed. The elevated transaminase levels would then resolve
over several days (Fig. 1). Peak bilirubin concentration was
significantly higher in patients with CMV syndrome, with a
median peak of 78 mmol compared with 26 mmol in patients
with MMA syndrome (P Å .004, Table 3). AST and ALT
levels were both significantly greater in patients with MMA,
with median values of 241 U/L and 350 U/L, compared with
102 U/L and 164 U/L in patients with CMV hepatitis (P Å
.0001 and .014, respectively). Alkaline phosphatase levels
were not significantly different between these two groups.
The initial histological distinctions between MMA syn-
drome and CMV infection was borne out by reviewing liver
biopsy specimens from a larger number of patients. The mi-
croabscesses were smaller in MMA syndrome and more nu-
merous than those in CMV infection (Figs. 2 and 3 and Table
4). MMAs were confined to the hepatic lobules, with no FIG. 1. Time course of AST and ALT concentration changes in 2 patients
with MMA syndrome. Arrows indicate the day of biopsy. Patient 1 was ainvolvement of portal tract structures. By definition, no CMV
6-year-old boy who had undergone OLT for biliary atresia approximately 5inclusion bodies were found in MMAs.
years before the episode of MMA syndrome. He had a 1-month history of
CMV DNA was not identified in any of the 14 biopsy headache and then sudden onset of fever, lethargy, and nausea coinciding
specimens studied from patients with MMA, despite success- with an abrupt increase in ALT and AST levels. His CMV IgM antibodies
were positive and he received ganciclovir intravenously for a total of 4ful amplification of intact DNA in each of these cases as
weeks’ postbiopsy. Patient 2 was a 51-year-old woman who had undergoneevidenced by successful amplification of b-hemoglobin DNA.
OLT approximately 6 years before this episode of MMA syndrome for aIn contrast, 18 of 19 biopsy specimens with CMV inclusion
diagnosis of cryptogenic cirrhosis. She was being investigated for chronic
bodies were positive for DNA by PCR. The one biopsy speci- diarrhea when it was noted that her ALT and AST levels were elevated. The
men with CMV inclusions that was negative for CMV DNA increase in transaminase levels was not associated with onset of any new
symptoms. A liver biopsy showed the typical histological features of MMAby PCR contained only a single CMV inclusion in 17 tissue
syndrome. She did not receive ganciclovir during this, her second episodelevels. The failure to amplify CMV DNA from this biopsy
of MMA syndrome.
was presumably a consequence of a lack of an infected cell
in the tissue section used for DNA extraction. In the control
group of 28 liver transplant biopsy specimens without CMV
inclusions or MMAs, 11 (39%) were positive for CMV DNA
by PCR. The positive and negative controls run in parallel
with the tested samples reacted appropriately.TABLE 3. Peak Bilirubin, AST, ALT, and Alkaline Phosphatase Levels in
Patients With MMA Syndrome or CMV Infection in the 3 Days Before Figure 4 shows Kaplan-Meier plots of the raw data for the
to 1 Day After Diagnostic Liver Biopsy effect of MMA syndrome on patient and graft survival in
OLT recipients. When the time to diagnosis of MMA wasMMA Syndrome CMV Infection P
incorporated into the Cox proportional hazard survival
Bilirubin (mmol) 26 (5.1-112.2) 78 (14-646) .004 model as a time-dependent variable, there was no significant
AST (U/L) 241 (38-2481) 102 (32-250) .0001 effect on either patient or graft survival (Table 5). The esti-
ALT (U/L) 320 (51-1278) 164 (45-617) .014 mated (adjusted for age and sex) 1- and 5-year patient sur-
ALP (U/L) 279 (88-1353) 388 (108-1123) .80
vival rates for all OLT recipients were 74.8% (95% confidence
NOTE. Data given as median (range). interval [CI] 71.0-78.5) and 65.5% (95% CI 61.4-69.6), re-
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TABLE 4. Comparison of Histological Features of MMA Syndrome and
CMV Infection in Transplanted Livers
MMA Syndrome CMV Infection
Lesions/mm2 of biopsy 0.92* 0.049
Neutrophils/lesion 3-15 10-40
CMV inclusions or necrotic hepatocyte? No Yes
* P õ .0001.
could not be detected by nested PCR. The biochemical fea-
tures that help distinguish MMA syndrome from CMV infec-
tion include a greater elevation of AST and ALT levels but a
lower peak bilirubin concentration than that observed in
CMV infection. However, there is overlap between the two
conditions with respect to clinical and biochemical features.
FIG. 2. High-power photomicrograph showing an MMA composed of MMA syndrome can occur at any time after OLT, whereas
only a few neutrophils and Kupffer cells. Note the small size of this lesion CMV hepatitis tends to occur early after OLT. Additionally,
compared with the CMV-associated microabscess in Fig. 3. (Original magni- MMA syndrome occurred more frequently than CMV hepati-
fication 1230.)
tis in our review of OLT liver biopsies. Consequently, we
found that MMA syndrome was more likely than CMV hepa-
titis if microabscesses were present in liver biopsy specimens
spectively, whereas the estimated 1- and 5-year graft survival from patients who were 3 or more months post-OLT. MMA
rates were 66.7% (95% CI 62.6-70.8) and 57.2% (95% CI syndrome predominantly affects female OLT recipients but
52.9-61.5), respectively. Patient survival was not dependent is not related to the indication for first OLT or the age of
on recipient age or sex (P Å .74 and .58, respectively; Table patients. Importantly, MMA syndrome does not appear to
5) and graft survival was also not affected by recipient age have a negative effect on either patient or graft survival.
or sex (P Å .53 and .32, respectively). There was little evi- The Kaplan-Meier plots (Fig. 4) show an apparent benefi-
dence to suggest that the proportional-hazards assumption cial effect of MMA syndrome on both patient and graft sur-
was violated for patient and graft survival (for patient sur- vival. However, MMA syndrome occurs a variable time after
vival, P Å .71 across ages and .23 across sexes; for graft OLT (range, 4-2,186 days). Most MMA patients are ‘‘selected’’
survival, P Å .06 across ages and .10 across sexes). from the pool of patients who survive the peri-transplanta-
tion period. Thus, the MMA group has relatively little graft or
DISCUSSION patient loss in the perioperative period; however, the Kaplan-
Meier plots then parallel those for all OLT recipients. ThisMMA syndrome is a histologically diagnosed syndrome
explains, at least in part, the apparent benefit for patient andcharacterized by numerous, small microabscesses confined
graft survival in patients with MMA syndrome seen in theseto the hepatic lobules. These features serve to distinguish
plots. Incorporating the time post-OLT to diagnosis of MMAMMA syndrome from CMV infection in which the microab-
into the proportional-hazards model as a time-dependentscesses are larger and in which biliary epithelium and endo-
variable controls for this potential source of bias. With thisthelial cells are also infected. In addition, CMV inclusion
modeling, MMA syndrome had no significant effect on pa-bodies are not found in MMA syndrome, and CMV DNA
tient or graft survival.
The typical presentation of MMA syndrome is of a clini-
cally well female OLT recipient who has recovered from the
perioperative OLT period and is attending a routine OLT
outpatient appointment. Significant elevation of transami-
nase levels is detected on pre-outpatient clinic blood work.
The elevated transaminase levels result in sufficient concern
at the outpatient visit for an urgent liver biopsy to be ar-
ranged. This liver biopsy shows the typical histological ap-
pearance of MMA syndrome. The liver enzymes return to
their usual level over several days.
Early in our experience with minimicroabscess syndrome
we were concerned that the MMAs were caused by CMV. As
our experience increased it became apparent that the clinical
and histological features of MMA syndrome were quite dis-
tinct from CMV infection. However, the strongest evidence
that CMV infection is not the cause of MMA syndrome comes
from the CMV PCR results. CMV DNA could not be detected
in any of the 14 MMA biopsy specimens tested, whereas the
FIG. 3. High-power photomicrograph showing a CMV-infected hepato- internal b-hemoglobin control was amplified in all cases. Thecyte with characteristic amphophilic nuclear inclusion. The surrounding
technique was able to detect CMV DNA in 18 of 19 biopsyparenchyma shows a microabscesss composed of numerous (ú20) neutro-
phils. specimens with CMV inclusion bodies present, and was also
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TABLE 5. Hazards Ratios for Patient and Graft Survival by MMA Status,positive in a third of randomly selected OLT liver biopsy
Recipient Sex, and Agespecimens. Nested PCR for the detection of CMV DNA from
formalin-fixed, paraffin-embedded tissue has been shown to Patient Survival Graft Survival
be extremely sensitive, with a negative predictive value of
MMA statusup to 100%.16,18-20 This sensitivity occurs at the expense of
Absent 1.00 1.00specificity and the presence of CMV DNA in a biopsy does
Present 0.54 (0.22-1.33) 0.71 (0.33-1.52)
not mean there is active CMV infection. However, the failure Sex
to detect CMV DNA with this technique is powerful evidence Male 1.00 1.00
that CMV is not an etiologic factor for MMA syndrome. Female 1.10 (0.78-1.54) 1.17 (0.86-1.59)
Although CMV infection can be excluded as the cause of Age group (yr)
°28 1.00 1.00MMA syndrome, the etiology of MMA syndrome is not clear.
29-40 0.73 (0.43-1.23) 0.71 (0.44-1.14)There are some epidemiological clues to the etiology of MMA
41-48 0.93 (0.57-1.53) 0.89 (0.57-1.38)syndrome. The predominance of female OLT recipients in
49-56 0.88 (0.52-1.47) 0.80 (0.50-1.28)patients with MMA syndrome is interesting, but we have no
¢57 0.81 (0.48-1.36) 0.70 (0.44-1.12)explanation for it. If MMA syndrome was confined to recipi-
ents of a liver from an opposite sex donor then interactions NOTE. Data given as mutually adjusted estimates and 95% CI.
between circulating sex hormones and sex hormone recep-
tors could be responsible. However, MMAs were also de-
tected in patients who received a liver from a same-sex donor.
MMA syndrome is not related to the indication for first OLT,
and therefore does not appear to be due to a recurrence of the
disease that resulted in OLT. Additionally, MMA syndrome is
usually diagnosed 2 or more months after OLT, when most
patients have recovered from the surgery. This implies MMA
syndrome is not a consequence of the transplantation sur-
gery. Finally, MMAs are not age specific and have been de-
tected in liver biopsy specimens from pediatric and adult
OLT recipients.
Viral agents other than CMV implicated in viral hepatitis
post-OLT include herpes simplex, Epstein-Barr virus, and
adenovirus.21-26 Histologically, herpes simplex–associated
hepatitis has areas of coagulative necrosis not confined to
the hepatic lobule, and occasional hepatocytes at the edge of
the necrotic foci contain nuclear inclusions.21,24 Epstein-Barr
virus infection has a variable appearance that ranges from a
sinusoidal lymphocytosis, to a monomorphic immunoblastic
lymphoma-like infiltrate of liver parenchyma.21 These ap-
pearances are characteristic and sufficient to discriminate
these infections from MMAs.
Microabscess formation can occur with adenovirus-associ-
ated hepatitis.23,26 However, areas of coagulative necrosis
similar to, but smaller than, those observed in herpes sim-
plex–associated hepatitis are described in adenovirus-associ-
ated hepatitis, and intranuclear inclusion bodies are typically
present.21,23-25 Additionally, adenovirus-associated microab-
scesses are larger than those found in CMV infection, distin-
guishing it from MMA syndrome.21,23 Adenoviral hepatitis
has predominantly been reported in pediatric OLT recipients,
particularly in the first 3 months after OLT, and up to 45%
of pediatric OLT recipients with invasive adenoviral infection
die.21-24,26 For these reasons, adenoviral hepatitis in OLT re-
cipients appears histologically and clinically distinct from
MMA syndrome.
FIG. 4. Kaplan-Meier plots of patient and graft survival rates in all OLT In summary, MMA syndrome in OLT recipients is a histo-
recipients and in patients with MMA syndrome. There is an apparent benefit
logical diagnosis that is based on a finding of numerousin the MMA group for both patient and graft survival. This apparent benefit
MMAs confined to the hepatic lobules in the absence ofis present, in part, because most patients with MMA syndrome have survived
the peritransplant period. Their survival appears better than for all OLT inclusions. Although the clinical picture can be suggestive,
recipients because they are ‘‘selected’’ from the group of patients who have it is not possible to distinguish MMA syndrome from other
survived the relatively high graft and patient loss that occurs at and shortly causes of abnormal liver enzyme levels without performingafter OLT. When the time to onset of MMA syndrome is considered in the
a liver biopsy. The etiology of MMAs is unclear but does notproportional-hazards model, there is no significant benefit in terms of graft
or patient survival for patients with MMA syndrome. appear to be caused by CMV, herpes simplex, or adenovirus
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